Anesiva, Inc.
https://www.anesiva.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Anesiva, Inc.
Ensho Joins Race To Develop An Oral Integrin Inhibitor For IBD
Ensho Therapeutics is raising series A cash to develop Phase II-ready NSHO-101 (EA1080), a third oral ɑ4β7 integrin inhibitor attempting to take on Takeda’s blockbuster injectable Entyvio.
340B Drug Diversion: Sanofi Suit Seeks Evidence In Pharmacy Contracts With Hospitals
Drug maker pursuing novel approach to establishing that contract pharmacies are improperly taking ‘title’ to 340B-discounted drugs, leading to diversion, which is prohibited by law.
Teva Pulls Out Its Digital Inhaler GoResp From UK Market
Commercial reasons led Teva to withdraw its innovative GoResp Digihaler from the UK market, asking healthcare professionals to stop supplying the inhaler immediately.
BIO: Bayer Operational Model Benefits From Its Arm’s Length Biotechs
There is a lot of structural change going on at the German major but it is learning from the way its wholly owned subsidiaries such as AskBio and BlueRock are run.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- AlgoRx Pharmaceuticals
- Corgentech
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice